We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
View Top Employees from Inozyme Pharma| Website | http://www.inozyme.com |
| Revenue | $8 million |
| Funding | $228 million |
| Employees | 76 (76 on RocketReach) |
| Founded | 2016 |
| Address | 321 Summer St Suite 400, Boston, Massachusetts 02210, US |
| Phone | (857) 330-4340 |
| Technologies |
JavaScript,
HTML,
PHP
+30 more
(view full list)
|
| Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Healthcare, Science and Engineering, Health Care, Medical, Pharmaceutical |
| Competitors | Alios BioPharma, Leap Therapeutics, Magenta Therapeutics, Orphazyme A/S, Visterra Inc. |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular Inozyme Pharma employee's phone or email?
Inozyme Pharma Questions
The Inozyme Pharma annual revenue was $8 million in 2024.
Axel Bolte is the Co-Founder of Inozyme Pharma.
76 people are employed at Inozyme Pharma.
Inozyme Pharma is based in Boston, Massachusetts.
The NAICS codes for Inozyme Pharma are [325, 3254, 32, 32541].
The SIC codes for Inozyme Pharma are [28, 283].
Top Inozyme Pharma Employees
-
5+5+
-
52
-
ViewGus Khursigara
Vice President, Medical Affairs and Clinical Strategy at Inozyme Pharma
Cambridge, MA, US32 -
22
-
23
-
12
-
43
-
35+
-
22
-
13
Related Companies
